ReviewAntibody therapeutics2024
Further accelerating biologics development from DNA to IND: the journey from COVID-19 to non-COVID-19 programs.
Kee Wee Tan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it